We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+37.79%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$2.62B
AUM Growth
+$630M
Cap. Flow
+$142M
Cap. Flow %
5.42%
Top 10 Hldgs %
54.13%
Holding
172
New
46
Increased
29
Reduced
19
Closed
33
Avg Time Held Equity + Options
4.2 quarters
Top 10 Avg Time Held Equity + Options
5.4 quarters
Top 20 Avg Time Held Equity + Options
5.4 quarters
Avg Time Held Equity only
4.4 quarters
Top 10 Avg Time Held Equity only
5.4 quarters
Top 20 Avg Time Held Equity only
5.5 quarters

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$64.1M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$36.1M
3
XLRN
Acceleron Pharma
XLRN
+$31.4M
4
PBYI icon
Puma Biotechnology
PBYI
+$17.7M
5
CBAY icon
Cymabay Therapeutics
CBAY
+$15.9M

Top Sells

Rank Stock Value
1
ARAV
Aravive, Inc. Common Stock
ARAV
+$42.4M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$36.7M
3
RDUS icon
Radius Health, Inc.
RDUS
+$29.2M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$20.9M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.22%
2 Miscellaneous 1.22%
3 Industrials 0.33%
4 Consumer Staples 0.16%
5 Consumer Discretionary 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
TVRD icon
151
CALL
Tvardi Therapeutics
TVRD
$13.9M
– –
-2,778
Closed -$1.54M –
CDMO icon
152
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
– –
-3,476
Closed -$15K –
EGRX icon
153
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
– –
-100,000
Closed -$7.89M –
DMK
154
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
– –
-5,714
Closed -$2.08M –
ZYNE
155
PUT
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
– –
-100,000
Closed -$10.2M –
SYNH
156
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
– –
-8,532
Closed -$499K –
ACOR
157
DELISTED
Acorda Therapeutics
ACOR
– –
-265
Closed -$626K –
SIOX
158
CALL
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-37,500
Closed -$6.96M –
SIOX
159
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-71,588
Closed -$13.3M –
LHCG
160
DELISTED
LHC Group LLC
LHCG
– –
-10,730
Closed -$728K –
RDUS icon
161
DELISTED
Radius Health, Inc.
RDUS
– –
-645,873
Closed -$29.2M –
RDUS icon
162
PUT
DELISTED
Radius Health, Inc.
RDUS
– –
-200,000
Closed -$9.05M –
HRC
163
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
– –
-7,930
Closed -$631K –
DPLO
164
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
– –
-30,658
Closed -$454K –
WCG
165
DELISTED
Wellcare Health Plans, Inc.
WCG
– –
-5,056
Closed -$908K –
FWP
166
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
– –
-27,817
Closed -$3.96M –
ONSIW
167
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
– –
-462,500
Closed -$80K –
ONSIZ
168
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
– –
-462,500
Closed -$42K –
3 4 5 6
7

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q3 2017 Portfolio in Review

As of Q3 2017, Perceptive Advisors held 172 positions worth $2.62B, up 32% from $1.99B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Perceptive Advisors deployed $142M of net new capital in Q3 2017, opening 46 new positions and adding to 29 existing holdings. Its largest new stake was Cymabay Therapeutics: 2,350,882 shares worth $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Industrials.

On the sell side, the largest reduction was Aravive, Inc. Common Stock, an estimated $42.4M trimmed.

  • Perceptive Advisors's largest Q3 2017 buy was Cymabay Therapeutics: 2,350,882 shares worth $18.9M.
  • Perceptive Advisors added most to Neurocrine Biosciences in Q3 2017, an estimated $64.1M increase.
  • Perceptive Advisors's biggest Q3 2017 reduction was Aravive, Inc. Common Stock, cutting an estimated $42.4M.
  • Perceptive Advisors fully exited Sarepta Therapeutics in Q3 2017, selling an estimated $36.7M.
  • Perceptive Advisors's ten largest holdings make up 54% of its $2.62B portfolio in Q3 2017.
  • Perceptive Advisors opened 46 new positions and closed 33 in Q3 2017.
  • Perceptive Advisors's portfolio value rose 32% quarter-over-quarter to $2.62B.

Based on Perceptive Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.